SCHEMBL22700154

SCHEMBL22700154

COc1ccc(COC[C@H]2OC(OC(C)=O)[C@@H](C)C2O[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GJB2 P29033 1/20 0.38
GJA1 P17302 1/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP2C9 P11712 2/20 0.36
CYP3A4 P08684 2/20 0.36
TP53 P04637 1/20 0.36
NT5E P21589 1/20 0.35
CYP2D6 P10635 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
SLC2A1 P11166 1/20 0.34
CA12 O43570 2/20 0.34
CA9 Q16790 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5827960 0.74 GJB2 (0.41) GJB2GJA1
SCHEMBL17472165 0.72 CYP2D6 (0.33) MEN1KMT2ACYP2C9CYP2D6SMN1; SMN2
SCHEMBL6656364 0.71 GJB2 (0.39) GJB2GJA1HDAC4HDAC6CA2
SCHEMBL14416241 0.71 NT5E (0.45) GJB2NT5ECYP2D6MAPK1ALDH1A1
SCHEMBL14414835 0.70 LMNA (0.47) KMT2ATP53NT5ELMNA
SCHEMBL14414832 0.70 LMNA (0.47) KMT2ATP53NT5ELMNA
SCHEMBL18499303 0.69 LMNA (0.47) KMT2ANT5ECYP2D6LMNAMAPK1
SCHEMBL22073057 0.69 NT5E (0.49) MEN1KMT2ACYP2C9CYP3A4TP53
SCHEMBL23867774 0.68 LMNA (0.56) KMT2ANT5ECYP2D6LMNAMAPK1
SCHEMBL16409716 0.68 CYP2D6 (0.33) CYP2D6LMNACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512860-B1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC (CA) 2020-11-25 EP disclosed